Supreme Court Decision Hangs In Balance After Hikma-Amarin Skinny-Label Oral Arguments
For the US generics industry, all eyes are on the Supreme Court as it considers the long-running skinny-label carve-outs dispute between Hikma and Amarin over Vascepa. Oral arguments in the case took place today and Generics Bulletin brings you the key points from the session.
Generics Bulletin - April 29, 2026

Biogen Plans Commercial Push Behind Empaveli And Syfovre
CEO Chris Viehbacher said the company will update investors on the 2026 financial outlook for Biogen incorporating the Apellis acquisition when it reports Q2 financials.
Scrip - April 29, 2026

Zimmer Biomet Advances Monogram To FDA, Says Stryker Cyberattack Had No Q1 Impact
Zimmer Biomet's Monogram robot cleared its clinical trial. Paragon 28 entered the teens. Technology sales grew 30%. But Stryker's cyberattack disruption moved no meaningful business its way.
Medtech Insight - April 29, 2026

Regeneron’s Pipeline In Focus As Fianlimab Melanoma Data Awaited
Regeneron's strong first quarter took a back seat to investor anxiety over its pipeline, with a key readout for its LAG 3 drug fianlimab expected sometime this quarter.
Scrip - April 29, 2026

Three Deaths Linked To Early Alert For Bolton Medical RelayPro Thoracic Stent-Graft
The US FDA has issued an early alert concerning a stent-graft system from Bolton Medical that is used to repair damaged or weakened sections of the thoracic aorta. The FDA reports three deaths associated with the system.
Medtech Insight - April 29, 2026

UK Price Rises Unlock AstraZeneca Investment, But Soriot Wants More
After falling out with the UK government last year over market access, AstraZeneca has now committed £300m to the country – and wants to see similar most favored nation-style deals struck across Europe.
Scrip - April 29, 2026

Weleda Reinvention Boosts Appeal Among Gen Z
Partnering with influencers helps Weleda to reach younger consumers with established cosmetic brands like Skin Food and new products such as Booster Drops.
HBW Insight - April 29, 2026

GSK Chief Miels Gets Boots Dirty To Prime The Pipeline
The UK major is completing a review of over 50 projects to select the most promising prospects and will rapidly allocate resources to the ones most likely to succeed in Phase III.
Scrip - April 29, 2026

Quotables: Pharma Leaders On The Month’s Hot Topics
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Scrip - April 29, 2026

Puig Says No Decision On Estée Lauder Merger As Talks Continue
Puig and The Estée Lauder Companies are still in discussions on a potential merger, new CEO Jose Manuel Albesa told analysts during an April 28 first quarter presentation.
HBW Insight - April 29, 2026

Five-Minute Podcast: A More Strategic View Of Innovation In Wales
The Life Sciences Hub Wales has honed is focus on early diagnosis and therapy for cancer and cardiovascular disease.
Medtech Insight - April 29, 2026

Dr Reddy’s Gets First Ozempic Rival In Canada, With Competition Imminent
With Canada one of the early markets earmarked for generic competition to semaglutide, Dr Reddy’s has taken a leading position through the first Health Canada approval for a rival to Ozempic.
Generics Bulletin - April 29, 2026

Pfizer’s Clean Sweep Closes US Vyndamax Litigation
Generic challengers Hikma, Cipla and Dexcel Pharma have secured a 2031 US entry date for generic tafamidis after settling with Pfizer, crystallizing a sizeable opportunity in the lucrative transthyretin-mediated amyloidosis space.
Generics Bulletin - April 29, 2026

A Tale Of Two Segments: Sandoz Biosimilars Sales Soar As Generics Dip
With its biosimilars sales shooting up as the generics business remains more muted, Sandoz’s first-quarter results call offered the opportunity for updates on upcoming biosimilar launches, generic portfolio rationalization, Chinese antibiotic price-dumping and the GLP-1 opportunity on the horizon.
Generics Bulletin - April 29, 2026

Five Questions We’re Asking About The Sun-Organon Deal
Long rumored and undeniably transformational, Sun Pharma’s $11.75bn move for Organon marks a bold leap onto the global stage. But, as Generics Bulletin explores, a series of critical questions will determine whether the deal delivers on its promise.
Generics Bulletin - April 29, 2026

First Mover Edge For Dr Reddy’s Semaglutide In Canada: Can It Capitalize?
Canada greenlights Dr Reddy’s generic semaglutide injection, bolstering the Indian firm’s GLP-1 growth story in what it sees as a ‘priority’ market.
Scrip - April 29, 2026

MDR Breakthrough Medical Device Pilot Begins
EMA is taking on responsibility for a new regulatory pathway that borrows a page from the US FDA’s book.
Medtech Insight - April 29, 2026

Why Haleon Is Reframing Sustainability Around ‘Enduring Resilience’
Exclusive: Haleon is reframing its sustainability strategy around long-term business resilience, focusing on material risks like climate-threatened ingredient supply chains rather than broad ESG commitments, Haleon’s VP of health inclusivity and sustainability, Sarah McDonald, tells HBW Insight.
HBW Insight - April 29, 2026

AstraZeneca’s Pitch For Crestor 5Mg OTC Switch Includes ‘30M Patient Years’ Safety History
Less than 50% of people who meet guideline criteria for statins are using the drugs. AstraZeneca’s OTC actual use trial shows those consumers are interested in treatment and can accurately self-select 5mg rosuvastatin.
HBW Insight - April 29, 2026